Aggregated News

Investors appeared optimistic Monday that November's election will benefit companies working with human embryonic stem cells, trading heavily in usually lightly traded biotech firms and driving share prices past 52 week highs.

Sen. John Kerry promises if elected to quadruple the $25 million in annual federal funding President Bush has made available for the controversial research. In California, voters will decide Nov. 2 if the state will borrow $3 billion to fund work with human embryonic stem cells during the next 10 years when they consider Proposition 71.

The stock run-up of the few companies involved with stem cells began Oct. 18 when Gov. Arnold Schwarzenegger endorsed the measure. The buying peaked Monday, even as an opposition campaign decried the proposition as "corporate welfare" and complained about a public subsidy benefiting biotechnology interests.

California stem cell researchers, including corporate scientists, would be eligible to receive part of the nearly $300 million that would be doled out annually during the next 10 years.

Analysts expect the proposition to make California the world's leading stem cell center and prompt talented scientists to...